From the FDA Drug Label
BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Adults (16 Years and Older): The recommended starting dosage for monotherapy or adjunctive therapy is 50 mg twice daily (100 mg per day) Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day). Pediatric Patients (1 Month to less than 16 Years): The recommended dosage is based on body weight and is administered orally twice daily
The recommended use of Briviact (brivaracetam) is for the treatment of partial-onset seizures in patients 1 month of age and older. The recommended dosage for adults (16 years and older) is 50 mg twice daily (100 mg per day), which can be adjusted based on individual patient tolerability and therapeutic response to a range of 25-100 mg twice daily (50-200 mg per day). For pediatric patients (1 month to less than 16 years), the dosage is based on body weight and administered orally twice daily 1.
From the Research
Briviact (brivaracetam) is recommended as an adjunctive therapy for partial-onset seizures in patients with epilepsy, with a typical starting dose of 50 mg twice daily, which can be adjusted based on clinical response and tolerability to between 25-100 mg twice daily, as supported by the most recent and highest quality study 2. The medication works by binding to synaptic vesicle protein 2A (SV2A) in the brain, which helps regulate neurotransmitter release and stabilize neuronal excitability.
- Key points to consider when prescribing Briviact include:
- The medication can be initiated at the target dose without titration, and it is effective on the first day of use in a significant percentage of patients 2.
- Briviact has a favorable psychiatric adverse effect profile in controlled studies, although limited postmarketing data are available 2.
- Common side effects include drowsiness, dizziness, fatigue, and nausea, and patients should be monitored for mood changes or suicidal thoughts, as these can occur with antiepileptic medications.
- When discontinuing Briviact, it is recommended to gradually taper the dose rather than stopping abruptly to reduce the risk of increased seizure frequency. The most recent study 2 provides the strongest evidence for the recommended use and dosage of Briviact, and it is essential to consider this study when making clinical decisions.
- Additional studies 3, 4, 5 also support the use of Briviact as an adjunctive therapy for partial-onset seizures, but the most recent study 2 takes precedence in guiding clinical practice.